Search

Your search keyword '"Schreiber, Stefan"' showing total 4,420 results

Search Constraints

Start Over You searched for: Author "Schreiber, Stefan" Remove constraint Author: "Schreiber, Stefan"
4,420 results on '"Schreiber, Stefan"'

Search Results

2. Dynamic changes in extracellular vesicle-associated miRNAs elicited by ultrasound in inflammatory bowel disease patients

3. FixNCut: single-cell genomics through reversible tissue fixation and dissociation

7. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort

9. Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease

12. Depression and fatigue six months post-COVID-19 disease are associated with overlapping symptom constellations: A prospective, multi-center, population-based cohort study

13. Effects of lifestyle and associated diseases on serum CC16 suggest complex interactions among metabolism, heart and lungs

14. Tryptophan degradation as a systems phenomenon in inflammation – an analysis across 13 chronic inflammatory diseases

16. Serine metabolism is crucial for cGAS-STING signaling and viral defense control in the gut

17. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study

18. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

19. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure

21. Transethnic analysis of the human leukocyte antigen region for ulcerative colitis reveals not only shared but also ethnicity-specific disease associations.

22. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis

24. Cohort profile: the Food Chain Plus (FoCus) cohort

25. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

28. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility

29. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics

31. THU-254-YI Differential gene expression profiles of liver tissue, subcutaneous and visceral adipose tissue delineates severity of MASLD in heavily obese patients

35. Single-cell RNA sequencing of nasal mucosa for molecular and genetic analysis of chemosensory dysfunction in post-COVID patients

36. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

38. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study

40. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

41. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study

42. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

43. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

44. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease

45. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity

46. DNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon

47. Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients

48. Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease

49. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

50. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

Catalog

Books, media, physical & digital resources